These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease. den Bakker MA; Grünberg K; Boonstra A; van Hal PT; Hollak CE Histopathology; 2012 Aug; 61(2):324-6. PubMed ID: 22690977 [No Abstract] [Full Text] [Related]
24. Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Maródi L; Káposzta R; Tóth J; László A Blood; 1995 Dec; 86(12):4645-9. PubMed ID: 8541556 [TBL] [Abstract][Full Text] [Related]
25. [French results of enzyme replacement therapy in Gaucher's disease]. Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377 [TBL] [Abstract][Full Text] [Related]
26. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519 [No Abstract] [Full Text] [Related]
28. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029 [TBL] [Abstract][Full Text] [Related]
29. Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease? Agilli M; Ekinci S; Fidan G J Neuroimmunol; 2015 Feb; 279():39. PubMed ID: 25669998 [No Abstract] [Full Text] [Related]
30. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease. Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757 [TBL] [Abstract][Full Text] [Related]
31. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease. Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M; Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065 [No Abstract] [Full Text] [Related]
35. [Gaucher's disease: a second drug is now available]. Stirnemann J Rev Prat; 2003 Sep; 53(13):1401-2. PubMed ID: 14558259 [No Abstract] [Full Text] [Related]
37. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? Dornelles AD; de Oliveira Netto CB; Vairo F; de Mari JF; Tirelli KM; Schwartz IV Clin Ther; 2014 Jun; 36(6):990-1. PubMed ID: 24768190 [No Abstract] [Full Text] [Related]
38. Short-term withdrawal from imiglucerase: what can we learn from it? Hollak CE Blood Cells Mol Dis; 2011 Jan; 46(1):105-6. PubMed ID: 20684887 [No Abstract] [Full Text] [Related]